The recent FDA accelerated approval of EGFR TKI mobocertinib32 and EGFR-MET-targeted bispecific antibody amivantamab31 for the treatment of advanced-stage NSCLC harboring EGFR 20ins had altered the therapeutic algorithm for these patients. This evidence concerns the gene MET and non-small cell lung carcinoma.